Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson’s disease

Ever since its introduction 40 years ago l-3,4-dihydroxyphenylalanine (l-DOPA) therapy has retained its role as the leading standard medication for patients with Parkinson’s disease. With time, however, the shortcomings of oral l-DOPA treatment have become apparent, particularly the motor fluctuatio...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Brain
Päätekijät: Rosenblad, Carl, Li, Qin, Pioli, Elsa Y., Dovero, Sandra, Antunes, André SLM, Agúndez, Leticia, Bardelli, Martino, Linden, R. Michael, Henckaerts, Els, Björklund, Anders, Bezard, Erwan, Björklund, Tomas
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6658866/
https://ncbi.nlm.nih.gov/pubmed/31243443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awz176
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia